Literature DB >> 30514799

Long-term real-world results of ibrutinib therapy in patients with relapsed or refractory chronic lymphocytic leukemia: 30-month follow up of the Swedish compassionate use cohort.

Maria Winqvist1,2, Per-Ola Andersson3, Anna Asklid2, Karin Karlsson4, Claes Karlsson5,2, Birgitta Lauri6, Jeanette Lundin5,2, Mattias Mattsson7, Stefan Norin8, Anna Sandstedt9, Richard Rosenquist10, Florentin Späth11, Lotta Hansson5,2, Anders Österborg5,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30514799      PMCID： PMC6518914          DOI： 10.3324/haematol.2018.198820

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  8 in total

1.  Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group.

Authors:  Valentin Goede; Jasmin Bahlo; Viktoria Chataline; Barbara Eichhorst; Jan Dürig; Stephan Stilgenbauer; Gerald Kolb; Friedemann Honecker; Ulrich Wedding; Michael Hallek
Journal:  Leuk Lymphoma       Date:  2015-10-13

2.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal:  Blood       Date:  2015-02-19       Impact factor: 22.113

3.  Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.

Authors:  Anthony R Mato; Colleen Timlin; Chaitra Ujjani; Alan Skarbnik; Christina Howlett; Rahul Banerjee; Chadi Nabhan; Stephen J Schuster
Journal:  Br J Haematol       Date:  2017-02-21       Impact factor: 6.998

4.  Ibrutinib for relapsed/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients.

Authors: 
Journal:  Haematologica       Date:  2016-10-18       Impact factor: 9.941

5.  Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Authors:  Maria Winqvist; Anna Asklid; P O Andersson; Karin Karlsson; Claes Karlsson; Birgitta Lauri; Jeanette Lundin; Mattias Mattsson; Stefan Norin; Anna Sandstedt; Lotta Hansson; Anders Österborg
Journal:  Haematologica       Date:  2016-05-19       Impact factor: 9.941

6.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

Authors:  Michael Hallek; Bruce D Cheson; Daniel Catovsky; Federico Caligaris-Cappio; Guillaume Dighiero; Hartmut Döhner; Peter Hillmen; Michael J Keating; Emili Montserrat; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

7.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

8.  Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Authors:  Anthony R Mato; Chadhi Nabhan; Meghan C Thompson; Nicole Lamanna; Danielle M Brander; Brian Hill; Christina Howlett; Alan Skarbnik; Bruce D Cheson; Clive Zent; Jeffrey Pu; Pavel Kiselev; Andre Goy; David Claxton; Krista Isaac; Kaitlin H Kennard; Colleen Timlin; Daniel Landsburg; Allison Winter; Sunita D Nasta; Spencer H Bachow; Stephen J Schuster; Colleen Dorsey; Jakub Svoboda; Paul Barr; Chaitra S Ujjani
Journal:  Haematologica       Date:  2018-02-01       Impact factor: 9.941
  8 in total
  16 in total

Review 1.  Real-World Evidence for Chronic Lymphocytic Leukemia in the Era of Targeted Therapies.

Authors:  Prioty Islam; Anthony R Mato
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

2.  Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.

Authors:  Sigrid S Skånland; Anthony R Mato
Journal:  Blood Adv       Date:  2021-01-12

3.  Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.

Authors:  Paul J Hampel; Timothy G Call; Kari G Rabe; Wei Ding; Eli Muchtar; Saad S Kenderian; Yucai Wang; Jose F Leis; Thomas E Witzig; Amber B Koehler; Amie L Fonder; Susan M Schwager; Daniel L Van Dyke; Esteban Braggio; Susan L Slager; Neil E Kay; Sameer A Parikh
Journal:  Oncologist       Date:  2020-09-20

4.  Effectiveness and Safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: 3-Year Follow-up of the Belgian Ibrutinib Real-World Data (BiRD) Study.

Authors:  Ann Janssens; Zwi N Berneman; Fritz Offner; Sylvia Snauwaert; Philippe Mineur; Gaetan Vanstraelen; Stef Meers; Isabelle Spoormans; Dominique Bron; Isabelle Vande Broek; Charlotte Van Bogaert; Birgit De Beleyr; Ann Smet; Lasse Nielsen; Robert Wapenaar; Marc André
Journal:  Clin Hematol Int       Date:  2022-10-13

Review 5.  Zanubrutinib in lymphoproliferative disorders: a comprehensive review.

Authors:  Javier Muñoz; Yucai Wang; Preetesh Jain; Michael Wang
Journal:  Ther Adv Hematol       Date:  2022-05-27

6.  Generating Evidence from Expanded Access Use of Rare Disease Medicines: Challenges and Recommendations.

Authors:  Tobias B Polak; David G J Cucchi; Joost van Rosmalen; Carin A Uyl-de Groot; Jonathan J Darrow
Journal:  Front Pharmacol       Date:  2022-05-23       Impact factor: 5.988

7.  Efficacy, safety, and quality of life of generic and innovator ibrutinib in Indian CLL patients.

Authors:  Charanpreet Singh; Nishant Jindal; Padma Youron; Pankaj Malhotra; Gaurav Prakash; Alka Khadwal; Arihant Jain; Sreejesh Sreedharanunni; Man Updesh Singh Sachdeva; Shano Naseem; Neelam Varma; Subhash Varma; Deepesh P Lad
Journal:  Indian J Hematol Blood Transfus       Date:  2020-11-13       Impact factor: 0.900

8.  Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Authors:  Antonio Cuneo; Robin Foà
Journal:  Mediterr J Hematol Infect Dis       Date:  2019-03-01       Impact factor: 2.576

9.  Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia.

Authors:  Jenny Klintman; Niamh Appleby; Basile Stamatopoulos; Katie Ridout; Toby A Eyre; Pauline Robbe; Laura Lopez Pascua; Samantha J L Knight; Helene Dreau; Maite Cabes; Niko Popitsch; Mats Ehinger; Jose I Martín-Subero; Elías Campo; Robert Månsson; Davide Rossi; Jenny C Taylor; Dimitrios V Vavoulis; Anna Schuh
Journal:  Blood       Date:  2021-05-20       Impact factor: 22.113

10.  Improved time to treatment failure and survival in ibrutinib-treated malignancies with a pharmaceutical care program: an observational cohort study.

Authors:  Jeremie Zerbit; Sylvie Chevret; Sophie Bernard; Marie Kroemer; Charlotte Ablard; Stephanie Harel; Pauline Brice; Isabelle Madelaine; Catherine Thieblemont
Journal:  Ann Hematol       Date:  2020-06-01       Impact factor: 3.673
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.